Myasthenia Gravis Therapeutics Market Pipeline Review, H2
2017
“Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis -
Pipeline Review, H2 2017, provides an overview of the Myasthenia Gravis
(Immunology) pipeline landscape.”
Summary
Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Pipeline Review, H2 2017,
provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape.
Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any
of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and
difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and
surgery.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Myasthenia Gravis - Pipeline Review, H2 2017, provides
comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology),
complete with analysis by stage of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest news and press releases.
Browse Detail Report With TOC @
http://www.hexareports.com/report/myasthenia-gravis-pipeline-review-h2-2017
Follow Us: